Citations

Showing 10 of 108094 citations.

What's in a name: are menopausal “hot flashes” a symptom of menopause or a manifestation of neurovascular dysregulation?
Miller, Virginia M. , Kling, Juliana M. , Files, Julia A. , Kapoor, Ekta , Moyer, Ann M. , Rocca, Walter A. , Kling, Juliana M , Joyner, Michael J. , Faubion, Stephanie S.

Mayo Clinic

Menopause | January 29, 2018 | Volume: 25 | Issue: 6 | Pages: 700-703

10.1097/gme.0000000000001065 | PMID 29381665 Get It

Abstract Hot flashes have typically been classified as “symptoms of menopause” that should be tolerated or treated until they resolve. However, mounting evidence points to hot flashes as a manifestation of one or several underlying pathophysiological processes. Associations exist between the presence, timing of onset, severity, and duration of hot flashes, and the risk of several neurological (affecting sleep, mood, and cognition) and cardiovascular conditions. In addition, four consistent patterns of vasomotor disturbances have been identified across different countries, making it unlikely that these patterns are solely explained by socioeconomic or cultural factors. The changing hormonal environment of menopause may unmask differences in the autonomic neurovascular control mechanisms that put an individual woman at risk for chronic conditions of aging. These differences may have a genetic basis or may be acquired across the life span and are consistent with the variability of the clinical manifestations of aging observed in women after bilateral oophorectomy. It is time to investigate the pathophysiological mechanisms underlying the four patterns of vasomotor symptoms more closely, and to shift from describing hot flashes as symptoms to be tolerated to manifestations of an underlying autonomic neurovascular dysregulation that need to be addressed.
Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis
Kattah, Andrea G. , Milić, Nataša , Kantarci, Kejal , Zeydan, Burcu , Kardia, Sharon L. R., Suarez, Maria L G, Turner, Stephen T. , Garovic, Vesna D. , Milic, N , Kantarci, Kejal , Zeydan, Burcu , Suarez, Maria Lourdes Gonzalez , Mosley, Thomas H. , Ware, Erin Bakshis

Mayo Clinic

Menopause | January 29, 2018 | Volume: 25 | Issue: 6 | Pages: 625-634

10.1097/gme.0000000000001062 | PMID 29381664 Get It

Abstract Objective: Experimental models suggest estrogen has a renoprotective effect, but human studies show variable results. Our objective was to study the association of hormone therapy (HT) and albuminuria in postmenopausal women and to synthesize the results with outcomes from prior studies. Methods: We analyzed data from postmenopausal women who participated in the second study visit (2000-2004) of the Genetic Epidemiology Network of Arteriopathy (GENOA) study. The exposure was self-reported HT use and the outcome was albuminuria (urine albumin-to-creatinine ratio >25 mg/g creatinine). We also conducted a systematic review and meta-analysis on the association of HT and urine protein in postmenopausal women. Continuous and dichotomous measures of protein excretion were converted to a standardized mean difference (SMD) for each study. Results: In the GENOA cohort ( n = 2,217), there were fewer women with albuminuria among HT users than nonusers (9% vs 19%, P < 0.001). HT use was associated with decreased odds of albuminuria (odds ratio 0.65, 95% confidence interval (CI), 0.45-0.95), after adjusting for significant differences in age, race, education, comorbidities, and the age at and cause of menopause. The SMD of the effect of HT on urine proteinuria/albuminuria in the randomized control trials ( n = 3) was 0.02 (95% CI, −0.29 to 0.33) and −0.13 (95% CI, −0.31 to 0.05) in the observational studies ( n = 9). There was significantly less albuminuria among HT users (SMD −0.15, 95% CI, −0.27 to −0.04) in the 9 studies that only reported albuminuria as an outcome and in the 10 studies with a comparator arm (SMD −0.15, 95% CI, −0.26 to −0.04). Conclusions: HT is associated with decreased odds of albuminuria, but some of the observed benefits may be related to reported outcomes, the presence of a comparator arm, and the type of study design.
Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state
Saadeh, Salwa , Litzow, Mark R. , Saadeh, Salwa S

Mayo Clinic

Expert Review of Hematology | January 29, 2018 | Volume: 11 | Issue: 3 | Pages: 195-207

10.1080/17474086.2018.1433030 | PMID 29376437 Get It

Do tetracyclines have the potential to reduce the risk of Clostridium difficile infection?
Khanna, Sahil

Mayo Clinic

Expert Review of Anti-infective Therapy | January 29, 2018 | Volume: 16 | Issue: 3 | Pages: 183-185

10.1080/14787210.2018.1434413 | PMID 29375022 Get It

Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities
Stewart, Michael

Mayo Clinic

Pharmaceutics | January 29, 2018 | Volume: 10 | Issue: 1 | Pages: 21

10.3390/pharmaceutics10010021 | PMID 29382038 Get It

Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of neovascularization and edema from several common chorioretinal vascular conditions. The intravitreally injected drugs (aflibercept, bevacizumab, conbercept, pegaptanib, and ranibizumab) used to treat these conditions improve the visual acuity and macular morphology in most patients. Monthly or bimonthly injections were administered in the phase III pivotal trials but physicians usually individualize therapy with pro re nata (PRN) or treat and extend regimens. Despite these lower frequency treatment regimens, frequent injections and clinic visits are still needed to produce satisfactory outcomes. Newly developed drugs and refillable reservoirs with favorable pharmacokinetic profiles may extend durations of action and require fewer office visits. However, we have learned from previous experiences that the longer durations of action seen in strategically designed phase III trials often do not translate to less frequent injections in real-life clinical practice. Unfortunately, long-acting therapies that produce soluble VEGF receptors (encapsulated cell technology and adenovirus injected DNA) have failed in phase II trials. The development of longer duration therapies remains a difficult and frustrating process, and frequent drug injections are likely to remain the standard-of-care for years to come.
Spontaneous coronary artery dissection: Acute findings on coronary computed tomography angiography
Akhtar, Nila J., Best, Patricia J.M. , Gulati, Rajiv , Araoz, Philip A. , Tweet, Marysia S. , Best, Patricia Jm, Hayes, Sharonne N.

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | January 29, 2018 | Volume: 8 | Issue: 5 | Pages: 467-475

10.1177/2048872617753799 | PMID 29376398 Get It

Background: The coronary computed tomography angiography features of acute spontaneous coronary artery dissection, an important cause of acute coronary syndrome in young women, have not been assessed. Methods: The “Virtual” Multicenter Mayo Clinic Spontaneous Coronary Artery Dissection Registry was established in 2010 and includes retrospective and prospective patient data. Retrospective assessment of acute coronary computed tomography angiography images was performed for 14 patients (16 vessels) who had images performed within two days of invasive coronary angiography diagnosis of acute spontaneous coronary artery dissection. Results: Four pertinent diagnostic coronary features of acute spontaneous coronary artery dissection were observed in order of prevalence: 1) abrupt luminal stenosis (64%); 2) intramural hematoma (50%); 3) tapered luminal stenosis (36%); and 4) dissection (14%). Additional findings include epicardial fat stranding (42%), coronary tortuosity (29%), and coronary bridge (14%). Fifty percent of patients had myocardial hypoperfusion in the myocardial distribution of the dissected coronary artery. Conclusions: We define key coronary computed tomography angiography features of acute spontaneous coronary artery dissection, the most common of which are abrupt luminal stenosis and intramural hematoma. Importantly, intramural hematoma appears similar to noncalcified atherosclerotic plaque, emphasizing the importance of invasive coronary angiography for acute diagnosis of spontaneous coronary artery dissection until the sensitivity and specificity of coronary computed tomography angiography is better understood.
Monitoring Neuromuscular Function
Brull, Sorin J. , Prielipp, Richard, Gutiérrez, Alexander, Cruz, Rossemary De La, Conley, Christopher , Ortega, Rafael, De La Cruz, Rossemary, Conley, Christopher M, Ortega, Rafael , Prielipp, Richard C., Brull, Sorin J

Mayo Clinic

New England Journal of Medicine | January 29, 2018 | Volume: 378 | Issue: 4 | Pages: No page available

10.1056/nejmvcm1603741 | PMID 29365307 Get It

Clinically Relevant Outcome Measures Following Limb Osseointegration; Systematic Review of the Literature
Muderis, Munjed Al , Lu, William , Li, Jiao Jiao , Orendurff, Michael S. , Highsmith, M. Jason , Lunseth, Paul A., Kahle, Jason T. , Kaufman, Kenton, Kaufman, Kenton R.

Mayo Clinic

Journal of Orthopaedic Trauma | January 28, 2018 | Volume: 32 | Issue: 2 | Pages: e64-e75

10.1097/bot.0000000000001031 | PMID 29373379 Get It

Objectives: The current standard of care for an amputee is a socket-based prostheses. An osseointegrated implant (OI) is an alternative for prosthetic attachment. Osseointegration addresses reported problems related to wearing a socket interface, such as skin issues, discomfort, diminished function, quality of life, prosthetic use, and abandonment. The purpose of this report is to systematically review current literature regarding OI to identify and categorize the reported clinically relevant outcome measures, rate the quality of available evidence, and synthesize the findings. Data sources: A multidisciplinary team used PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methods. Search methodology was based on identifying clinically relevant articles. Three databases were searched: PubMed, CINAHL, and Web of Science. Study Selection: Clinical studies with aggregated data reporting at least 1 clinically relevant outcome measure were included. Data Extraction: The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criterion was used for critical appraisal and recommendations. Conclusions: This review identified 21 clinically relevant observational studies. Outcome measures were categorized into the following 9 categories: vibratory stimulation, complications, biomechanics, economics, patient-reported outcome measures, electromyography, x-ray, physical functional performance, and energy consumption. This systematic review consisted of Level III and IV observational studies. Homogeneous outcome measures with strong psychometric properties across prospective studies do not exist to date. Higher-level, prospective, randomized, long-term, clinically relevant trials are needed to prove efficacy of OI compared with socket prosthetic attachment. Osseointegration was at least equivalent to sockets in most studies. In some cases, it was superior. Osseointegration represents a promising alternative to socket prosthetic attachments for extremity amputees. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance
Bhat, Mamatha , Mara, Kristin C. , Dierkhising, Ross , Watt, Kymberly D. , Mara, Kristin, Mara, Kristin C , Bhat, Mamatha

Mayo Clinic

Transplantation | January 28, 2018 | Volume: 103 | Issue: 1 | Pages: 91-100

10.1097/tp.0000000000002113 | PMID 29377876 Get It

Background Malignancy after liver transplant (LT) is a leading cause of mortality, but data is limited. The aim of this study was to identify patients at higher risk for de novo malignancies after LT in a large multicenter database. Methods The Scientific Registry of Transplant Recipients database comprising all 108 412 LT recipients across the United States between 1987 and March 2015 was analyzed with a median follow-up of 6.95 years. Potential risk factors for malignancies after LT were assessed using Cox regression analysis for the outcome of time to first malignancy. Results Mean age 51.9 ± 10.8 years, 64.6% male, 74.5% white, and 15.8% with previous malignancy. Malignancies during follow-up were 4,483 (41.3%) skin, 1519 (14.0%) hematologic, and 4842 (44.7%) solid organ. The 10-year probability of de novo malignancy was 11.5% (11.3-11.8%). On multivariable analysis, age by decade (hazard ratio [HR], 1.52; P < 0.001), male sex (HR, 1.28; P < 0.001), white race (compared with other races: HR, 1.45-2.04; P < 0.001), multiorgan transplant (HR, 1.35; P < 0.001), previous malignancy (HR, 1.34; P < 0.001), and alcoholic liver disease, autoimmune, nonalcoholic steatohepatitis (HR, 1.35; P < 0.001), and primary sclerosing cholangitis pre-LT (compared with hepatitis C virus, P < 0.001) were associated with higher risk of post-LT malignancy, but type of immunosuppression was not (P = NS). Conclusions This large data set demonstrates the effects of ethnicity/race and etiologies of liver disease, particularly nonalcoholic steatohepatitis as additional risk factors for cancer after LT. Patients with these high-risk characteristics should be more regularly and diligently screened.
Recurrent Syncope, a Clue in Amyloid Cardiomyopathy
Marin‐Acevedo, Julian A. , Sánchez-Álvarez, Catalina , Alsaad, Ali A. , Pagán, Ricardo J. , Sanchez-Alvarez, Catalina

Mayo Clinic

Case Reports in Medicine | January 28, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-6

10.1155/2018/1864962 | PMID 29559999 Get It

Infiltrative cardiomyopathies include a variety of disorders that lead to myocardial thickening resulting in a constellation of clinical manifestations and eventually heart failure that could be the first clue to reach the diagnosis. Among the more described infiltrative diseases of the heart is amyloid cardiomyopathy. The disease usually presents with subtle, nonspecific symptoms. Herein, we illustrate a case of recurrent syncope as the initial presenting symptom for systemic amyloid with polyneuropathy and cardiomyopathy as a cause of syncope. The article illustrates the role of advanced cardiac imaging in the diagnosis of the disease with a focused literature review. We also highlight the role of early, shared decision-making between patient, family, and medical team in the management of cardiac amyloidosis.